Daniel C. Martin - 30 Nov 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role: Chief Commercial Officer
Signature: /s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 30 Nov 2023
Net transactions value: -$223,755
Form type: 4
Filing time: 01 Dec 2023, 16:05:12 UTC
Previous filing: 31 Oct 2023
Next filing: 14 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DCPH	Common Stock	Sale	$223,755	-17,801	-28%	$12.57	45,435	30 Nov 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 352 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2023.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.56 to $12.625, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Content

Includes 352 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2023.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.56 to $12.625, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.